Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults

NCT04201457 is registered in ClinicalTrials.gov with Pediatric Brain Tumor Consortium as lead sponsor.

NCT NCT04201457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04201457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults
Lead sponsor
Pediatric Brain Tumor Consortium
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 17, 2020
Completion date
December 31, 2026
Enrollment
57 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

high grade glioma (hgg) of the brain with braf aberration, low grade glioma (lgg) of brain with braf aberration, low grade glioma of brain with neurofibromatosis type 1